Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) has announced it will release its third-quarter 2024 financial results on Thursday, October 31, 2024, before the U.S. financial markets open. Following this, the company's management will host a live webcast at 8 a.m. Eastern Time to review Madrigal's financial and operating results.
Interested parties can access the webcast through the Investor Relations section of Madrigal Pharmaceuticals' website. To ensure a timely connection, participants are advised to register at least 15 minutes before the scheduled start. The webcast will remain available for approximately two hours after the live event concludes.
Positive
- None.
Negative
- None.
News Market Reaction – MDGL
On the day this news was published, MDGL gained 1.89%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CONSHOHOCKEN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2024 financial results on Thursday, Oct. 31, 2024, prior to the open of the U.S. financial markets.
Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.
The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.
The webcast will be available approximately two hours after the live webcast.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
When will Madrigal Pharmaceuticals (MDGL) release its Q3 2024 financial results?
What time is Madrigal Pharmaceuticals' (MDGL) Q3 2024 earnings webcast?
How can I access Madrigal Pharmaceuticals' (MDGL) Q3 2024 earnings webcast?
How long will Madrigal Pharmaceuticals' (MDGL) Q3 2024 earnings webcast be available after the live event?
